We are live on ! Find out more
EVLV icon

Evolv Technologies

244 hedge funds and large institutions have $823M invested in Evolv Technologies in 2025 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 86 increasing their positions, 51 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 28

69% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 51

57% more capital invested

Capital invested by funds: $526M → $823M (+$297M)

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

15% more funds holding

Funds holding: 213244 (+31)

12.02% more ownership

Funds ownership: 51.49%63.51% (+12%)

21% less call options, than puts

Call options by funds: $14.5M | Put options by funds: $18.5M

Holders
244
Holders Change
+31
Holders Change %
+14.55%
% of All Funds
3.2%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
62
Increased
86
Reduced
51
Closed
28
Calls
$14.5M
Puts
$18.5M
Net Calls
-$3.95M
Net Calls Change
-$4.33M
Name Holding Trade Value Shares
Change
Change in
Stake
YIH
76
Y-Intercept (HK)
Hong Kong
$1.3M +$1.26M +172,436 New
EGM
77
Engineers Gate Manager
New York
$1.27M +$1.23M +168,826 New
TIP
78
Torray Investment Partners
Maryland
$1.24M +$1.2M +164,807 New
RhumbLine Advisers
79
RhumbLine Advisers
Massachusetts
$1.24M -$25.8K -3,533 -2%
HighTower Advisors
80
HighTower Advisors
Illinois
$1.24M -$3.16K -433 -0.3%
VCM
81
Voleon Capital Management
California
$1.21M +$1.17M +159,805 New
N
82
Numerai
California
$1.19M +$1.15M +157,537 New
Los Angeles Capital Management
83
Los Angeles Capital Management
California
$1.16M +$166K +22,750 +17%
Group One Trading
84
Group One Trading
Illinois
$1.16M -$367K -50,318 -25%
MCM
85
Moore Capital Management
New York
$1.13M
AllianceBernstein
86
AllianceBernstein
Tennessee
$1.08M +$70.8K +9,700 +7%
Principal Financial Group
87
Principal Financial Group
Iowa
$1.06M -$59.8K -8,195 -5%
Wells Fargo
88
Wells Fargo
California
$1.04M +$154K +21,058 +18%
Federated Hermes
89
Federated Hermes
Pennsylvania
$1.01M +$974K +133,414 New
CAU
90
Caxton Associates (UK)
$964K +$932K +127,699 New
SPC
91
Sigma Planning Corp
Michigan
$948K -$27.7K -3,800 -3%
N
92
Natixis
France
$874K +$845K +115,700 New
ACM
93
Aquatic Capital Management
Illinois
$855K +$826K +113,186 New
Prudential Financial
94
Prudential Financial
New Jersey
$845K +$707K +96,800 +639%
LCG
95
Lisanti Capital Growth
New York
$822K +$795K +108,849 New
Ameriprise
96
Ameriprise
Minnesota
$821K +$794K +108,732 New
BHCM
97
Brevan Howard Capital Management
Jersey
$820K -$161K -22,002 -17%
Legal & General Group
98
Legal & General Group
United Kingdom
$819K -$985 -135 -0.1%
Osaic Holdings
99
Osaic Holdings
Arizona
$814K +$711K +97,417 +1,000%
JP Morgan Chase
100
JP Morgan Chase
New York
$814K -$833K -114,124 -51%

EVLV Hedge Fund Activity: Q3 2025 in Review

244 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Evolv Technologies (EVLV) for Q3 2025, worth a combined $823M — up 57% from $526M a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new EVLV positions and 28 closed out — a net gain of 34 holders — while 86 added to existing stakes and 51 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $28.1M. The largest seller was Data Collective IV, cutting an estimated $34.2M.

  • 244 institutional investors held Evolv Technologies (EVLV) as of Q3 2025, up from 213 in Q2 2025.
  • Funds reported $823M of Evolv Technologies stock for Q3 2025, up 57% quarter-over-quarter.
  • 62 funds opened new Evolv Technologies positions in Q3 2025 and 28 closed out, a net change of +34 holders.
  • The largest Evolv Technologies buyer in Q3 2025 was Driehaus Capital Management, an estimated $28.1M added.
  • The largest Evolv Technologies seller in Q3 2025 was Data Collective IV, an estimated $34.2M sold.

Based on aggregated 13F filings for Q3 2025.